Hengrui Pharmaceuticals

Explore the latest insights on Hengrui Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Bio‑Thera Solutions, Ltd. (SHA: 688177) announced that China's National Medical Products Administration (NMPA) has approved the Marketing Authorization Application for its Secukinumab Injection (BAT2306), indicated for the treatment of psoriasis,…

October 23, 2026

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer’s Treatment Access

October 23, 2026

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

October 23, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Drug